达雷妥尤单抗治疗多重耐药免疫介导血栓性血小板减少性紫癜的疗效与安全性
法国血栓性微血管病参考中心开展全国性调查,纳入7例患者共9次达雷妥尤单抗治疗发作,其中8次因ADAMTS13复发而患者其他方面处于临床缓解,1次因利妥昔单抗不耐受于急性期给药。8次发作ADAMTS13活性改善,3例发生ADAMTS13复发,12个月无ADAMTS13复发生存率为56%,不良事件均为非严重输注相关反应。
要点
- 达雷妥尤单抗治疗后8次发作ADAMTS13活性改善,其中3次ADAMTS13恢复正常。
- 3例患者发生ADAMTS13复发,2例再次使用达雷妥尤单抗治疗成功。
- 5次发作出现达雷妥尤单抗相关不良事件,均为非严重输注相关反应。
核心结论
- 达雷妥尤单抗可能是不耐受或难治于利妥昔单抗的iTTP患者的有效治疗选择。
研究设计与样本
- 法国血栓性微血管病参考中心开展全国性调查,纳入7例接受达雷妥尤单抗治疗的iTTP患者共9次发作。
- 患者此前中位接受过3线治疗。
- 8次发作因ADAMTS13复发而患者其他方面处于临床缓解时给药,1次因利妥昔单抗不耐受于疾病急性期给药。
主要发现
- 8次发作在达雷妥尤单抗给药后ADAMTS13活性改善,其中3次ADAMTS13恢复正常。
- 3例患者发生ADAMTS13复发,其中2例再次使用达雷妥尤单抗治疗成功。
- 中位无ADAMTS13复发生存期未达到,12个月无ADAMTS13复发生存率为56%。
- 5次发作出现达雷妥尤单抗相关不良事件,均为非严重输注相关反应。
关键数值与推荐
- 9次发作中8次ADAMTS13活性改善,3次ADAMTS13恢复正常。
- 3例患者发生ADAMTS13复发,2例再次使用达雷妥尤单抗治疗成功。
- 12个月无ADAMTS13复发生存率为56%。
- 5次发作出现达雷妥尤单抗相关不良事件,均为非严重输注相关反应。
临床怎么用
- 原文结论认为达雷妥尤单抗可能是不耐受或难治于利妥昔单抗的iTTP患者的有效治疗选择,原文未据此给出具体用药推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The immunosuppressive treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP) in patients with intolerance or refractoriness to the B-cell depleting monoclonal antibody rituximab remains debated. Daratumumab, a plasma cell-directed monoclonal antibody targeting CD38, represents a therapeutic option, but data are scarce. The French Thrombotic Microangiopathies Reference Center conducted a nationwide survey on iTTP patients treated with daratumumab. Nine episodes from seven patients were identified. Treatment was administered for A Disintegrin And Metalloproteinase with ThromboSpondin-1 motifs, 13th member (ADAMTS13) relapses while patients were otherwise in clinical response (N = 8), or during the acute phase of the disease following rituximab intolerance (N = 1). Patients have received a median of three previous therapeutic lines. ADAMTS13 activity improved in eight cases following daratumumab administration, including three cases where ADAMTS13 normalized. ADAMTS13 relapses occurred in three patients; in two cases, retreatment with daratumumab was successful. Median ADAMTS13 relapse-free survival was not reached; 12-month ADAMTS13 relapse-free survival was 56%. Daratumumab-related adverse events occurred in five cases and were non-severe infusion-related reactions in all cases. These results suggest that daratumumab may be an effective treatment option for iTTP patients with intolerance or refractoriness to rituximab.
引用
- Weisinger J, Bouzid R, Ranta D, et al. Efficacy and safety of daratumumab in multiresistant immune-mediated thrombotic thrombocytopenic purpura. Br J Haematol. 2024. PMID: 39228246. doi:10.1111/bjh.19752
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。